-

Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026 at 8:40 a.m. EDT.

The presentation will be webcast live and can be accessed at Investor.Incyte.com and will be available for replay for 30 days.

About Incyte

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, and Instagram. 

Contacts

Media
media@incyte.com

Investors
ir@incyte.com

Industry:

Incyte

NASDAQ:INCY
Release Summary
Incyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Release Versions
English
$Cashtags
$INCY

Contacts

Media
media@incyte.com

Investors
ir@incyte.com

Social Media Profiles
Incyte/LinkedIn
@Incyte
More News From Incyte

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders...

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte's frontMIND trial found Tafasitamab (Monjuvi/Minjuvi) combo significantly prolongs progression-free survival in high-risk DLBCL patients...

Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development

WILMINGTON, Del. & SAN FRANCISCO--(BUSINESS WIRE)--Incyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development...
Back to Newsroom